Radiopharmaceuticals Market By End User (Hospitals and Clinics, Medical Imaging Centers, Others), By Radioisotope (Technetium 99m, Gallium 68, Iodine I, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, T

Radiopharmaceuticals Market By End User (Hospitals and Clinics, Medical Imaging Centers, Others), By Radioisotope (Technetium 99m, Gallium 68, Iodine I, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic): Global Opportunity Analysis and Industry Forecast, 2024-2033

The radiopharmaceuticals market was valued at $7.9 billion in 2023 and is estimated to reach $21.8 billion by 2033, exhibiting a CAGR of 10.6% from 2024 to 2033. Radiopharmaceuticals are medications that include radioactive versions of chemical elements known as radioisotopes. Depending on the type of radiation they emit, radioisotopes can be used to diagnose or treat a variety of medical diseases. Their uses range from examining and treating various organs, including the brain, heart, kidney, and bone, to the treatment of cancer and hyperthyroidism. Radiopharmaceuticals are administered to patients via injection or orally, and they may be monitored and analyzed using external medical equipment and testing. Most nations have specialized safety measures in place to safeguard patients and health workers from the potential harmful effects of these pharmaceuticals.
The radiopharmaceuticals market is primarily driven by the increase in prevalence of chronic diseases, rise in technological advancements, and growth in applications in diagnostic and therapeutic procedures. As the prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions continues to rise, there is a growing demand for effective diagnostic tools and targeted treatments. Radiopharmaceuticals, with their ability to provide precise imaging and therapeutic options, are increasingly recognized as valuable tools in the fight against these diseases. In addition, advancements in imaging techniques such as PET and SPECT have significantly improved the accuracy and efficiency of diagnosis, enabling early detection and better management of diseases propels the market growth. Additionally, the emergence of personalized medicine approaches has fueled the demand for radiopharmaceuticals, as they allow for tailored treatments on the basis of individual patient characteristics and molecular targets. However, the high cost associated with the development and production of radiopharmaceuticals can be prohibitive, thus hindering the market growth. This includes expenses related to research, clinical trials, and manufacturing processes, and regulatory compliance. The complex nature of radiopharmaceuticals also requires specialized infrastructure and expertise, further adding to the financial burden. In contrast, ongoing R&D activities for radiopharmaceuticals are increasingly being explored for use in areas such as theranostics, which involves combining diagnostic imaging with targeted therapy that provides lucrative opportunities for the market growth. The radiopharmaceuticals market is segmented on the basis of type, application, radioisotope, end user, and region. On the basis of type, the market is bifurcated into diagnostic, and therapeutic. On the basis of application, the market is classified into cancer, cardiology and others. The cancer segment is further classified into prostate cancer, breast cancer, gastrointestinal cancer, lung cancer, brain tumors, and others. The others segment further bifurcated into Neurological Applications and other applications. On the basis of radioisotope, the market is classified into Iodine I, Gallium 68, Technetium 99m, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, and others. On the basis of end user, the market is categorized into hospitals and clinics, medical imaging centers, and others. On the basis of region, the market is studied across North America (U.S. and Canada), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, Thailand, Malaysia, Indonesia, Singapore, Taiwan, Province Of China, and Rest of Asia-Pacific), and LAMEA (Brazil and Rest of LAMEA). Major key players that operate in the global radiopharmaceuticals market are Bayer AG, Cardinal Health, Eli Lilly and Company, Bracco, Isotopia Molecular Imaging Ltd., Actinium Pharmaceuticals, Inc., Novartis AG, Curium Pharma, Nihon Medi-Physics Co. Ltd., Jubilant Pharmova Limited, Eckert & Ziegler, NorthStar Radioisotopes, The State Atomic Energy Corporation ROSATOM, SOFIE, Lantheus, Telix Pharmaceuticals Limited, Clarity Pharmaceuticals, Fusion Pharmaceuticals Inc., PRECIRIX, ITM Isotope Technologies Munich SE, GE Healthcare, South African Nuclear Energy Corporation (Necsa), and Eczacibasi. Key players operating in the market have adopted agreement, acquisition, expansion, clinical trial, product approval, product upgrade, contract, product development, collaboration, geographical expansion, joint venture, and expansion, as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the radiopharmaceuticals market analysis from 2023 to 2033 to identify the prevailing radiopharmaceuticals market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global radiopharmaceuticals market trends, key players, market segments, application areas, and market growth strategies.
Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Historic market data

Key Market Segments

By End User

Hospitals and Clinics
Medical Imaging Centers
Others

By Radioisotope

Technetium 99m
Gallium 68
Iodine I
Fluorine 18
Copper 64
Strontium 89
Yttrium 90
Radium 223
Actinium 225
Lutetium 177
Copper 67
Terbium 161
Zirconium 89
Others

By Application

Cancer
Type
Prostate Cancer
Breast Cancer
Gastrointestinal Cancer
Lung Cancer
Brain Tumors
Others
Cardiology
Others
Type
Neurological Applications
Other Applications

By Type

Diagnostic
Therapeutic

By Region

North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Thailand
Malaysia
Indonesia
Singapore
Taiwan, Province Of China
Rest of Asia-Pacific
LAMEA
Brazil
Rest of LAMEA
Key Market Players
Cardinal Health
Eli Lilly and Company
Novartis AG
Jubilant Pharmova Limited
The State Atomic Energy Corporation ROSATOM
SOFIE
Telix Pharmaceuticals Limited
Clarity Pharmaceuticals
PRECIRIX
NorthStar Medical Radioisotopes
South African Nuclear Energy Corporation (Necsa)
Bayer AG
Bracco
Curium Pharma
Eckert & Ziegler
Lantheus
Nihon Medi-Physics Co. Ltd
Isotopia Molecular Imaging
ITM Isotope Technologies Munich SE
GE Healthcare
Actinium Pharmaceuticals, Inc.
Fusion Pharmaceuticals Inc.
Eczacibasi